Results 231 to 240 of about 3,256,020 (309)

Curcumin-based smart responsive hydrogels: A controlled release system for bone defect regeneration. [PDF]

Regen Ther
Huo J, Hui X, Lin M, Pan H, Hou D.
europepmc   +1 more source

Photochemically crosslinked collagen microspheres for controlled protein release

, 2007
So, KF, Chan, BP, Chan, CM
core  

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Agent-based modeling demonstrates how target-independent processes supplement killing by antibody-drug conjugates in cancer therapy. [PDF]

PLoS Comput Biol
Calopiz MC, Linderman JJ, Thurber GM.
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

AI comes to the Nobel Prize and drug discovery

Journal of Pharmaceutical Analysis
Ying Zhou, Yintao Zhang, Zhichao Zhang, Zhimeng Zhou, Feng Zhu   +4 more
doaj   +1 more source

Stimuli-Responsive Polypyrrole Hydrogel Integrated into a Mg Battery for Controlled Drug Release. [PDF]

ACS Omega
Mu Y, Fan J, Zhou Y, Liang Q, Tian Y.
europepmc   +1 more source

Washington's judicial mockery

, 1928
Centralia Release Committee
core